The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients

Psychopharmacology

Volumn 129, Issue 3, 1997, Pages 243-248

  Van Megen, Harold J G M ^a   Westenberg, Herman G M ^a   Den Boer, Johan A ^a   Slaap, Bernard ^a   Van Es Radhakishun, Fenny ^a   Pande, Atul C ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PFIZER INC   (United States)

Author keywords

CCK(B) receptor antagonist; Cholecystokinin; CI 988; Neuropeptide; Panic disorder

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; HYDROCORTISONE; PLACEBO; TETRAGASTRIN;

ADULT; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PANIC; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SYMPTOM;

ADOLESCENT; ADULT; ANTI-ANXIETY AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; INDOLES; MALE; MEGLUMINE; MIDDLE AGED; PANIC DISORDER; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; TETRAGASTRIN; TREATMENT OUTCOME;

EID: 0031045470     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050186     Document Type: Article

References (26)

1. Abelson JL, Nesse RM, Vinik AI (1994) Pentagastrin infusion in patients with panic disorder. II Neuroendocrinoloay. Biol Psychiatry 36:84-96
2. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM-IIIR). APA, Washington DC
3. Bammert-Adams J, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox Ch S, Wisselink PG, Greiner M, Pierce MW, Pande AC (1995) A double blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 15:428-434
4. Bradwejn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 48:603-610
5. Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H (1992b) Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am J Psychiatry 149:962-964
6. Bradwejn J, Koszycki D (1994) Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 151:261-263
7. Bradwejn J, Koszycki D, Couetoux du tertre A, Van Megen HJGM, Westenberg HGM, Den Boer JA, Karkanias C, Haigh J (1994) The panicogenic effects of cholecystokinin tetrapeptide are antagonized by L-365 260 a central cholecystokinin receptor antagonist in patients with panic disorder. Arch Gen Psychiatry 51:486-493
8. Bradwejn J, Koszycki D, Paradis M, Recce P, Hilnton J, Sedman A (1995) The effects of CI-988 on cholecystokinin tetrapeptide induced panic symptoms in healthy volunteers. Biol Psychiatry 38:742-746
9. Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN (1991) Anxiolytic effects of CCK-B antagonists. Neuropeptides 19 [Suppl.]:65-73
10. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296
11. Harro J, Vasar E (1991) Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour. Neurosci Biobehav Rev 15:473-477
12. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter C, Pinnock RD, Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728-6732
13. B antagonist, in panic disorder. Biol Psychiatry 37:462-466
14. Lines C, Challenor J, Traub M (1995) Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by cholecystokinin receptor subtype B antagonist L 365-260. Br J Pharmacol 39:235-242
15. Montigny de C (1989) Cholecystokinin tetrapeptide induces panic like attacks in healthy volunteers. Arch Gen Psychiatry 46:511-517
16. Powell KR, Barrett JE (1991) Evaluation of the effect of PD 134308 (C1-988), a CCK-B antagonist, on the punished responding of squirrel monkeys. Neuropeptides 19:75-78
17. SAS (1989) SAS/Stat User's Guide. Version 6.0, fourth edition, volumes 1 and 2. SAS Institute Inc., Gary, North Carolina
18. B receptor antagonist. Br J Pharmacol 104:239-245
19. Singh L, Field MJ, Vass CA, Hughes J, Woodruff GN (1992) The antagonism of the benzodiazepine withdrawal effects by the selective cholecystokinin-B antagonist CI-988. Br J Pharmacol 105:8-10
20. Thijssen JHH, Van den Berg JHM, Adlercreutz J (1980) Determination of cortisol in human plasma: evaluation and comparison of seven assays. Clin Chem Acta 100:39-46
21. Van Megen HJGM, Den Boer JA, Westenberg HGM (1994a) On the significance of cholecystokinin receptors in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 18:1235-1246
22. Van Megen HJGM, Westenberg HGM, Den Boer JA, Haigh JRM, Traub M (1994b) Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology 114:449-455
23. Van Megen HJGM, Westenberg HGM, Den Boer JA (1994c) Effect of the selective sorotonin reuptake inhibitor (SSRI) Fluvoxamine on CCK-4 induced panic attacks. CINP 1994. Psychopharmacology 10:270
24. Van Megen HJGM, Westenberg HGM, Den Boer JA (1996a) Effect of the cholecystokinin-B (CCK-B) receptor antagonist L-365, 260 on lactate induced panic attacks in panic disorder patients. Biol Psychiatry (in press)
25. Van Megen HJGM, Westenberg HGM, Den Boer JA, Kahn RS (1996b) The panic inducing properties of the cholecystokinin tetrapeptide CCK-4 in patients with panic disorder. Eur Neuropsychopharmacol (in press)
26. Woodruff GN, Hughes J (1991) Cholecystokinin antagonists. Annu Rev Pharmacol Toxicol 31:469-501